[Hormonal therapy for prostate cancer: methods and prognosis]

Area of Science:

• Oncology
• Urology
• Endocrinology

Background:

• Prostate cancer progression to androgen-independent prostate cancer (AIPC) remains a clinical challenge.
• Hormonal therapies are the mainstay for managing advanced prostate cancer.
• Optimizing androgen deprivation strategies is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of a modified intermittent androgen deprivation (IAD) therapy in delaying prostate cancer progression.
• To compare the modified IAD approach with continuous androgen deprivation (CAD) and standard IAD.

Main Methods:

• A study involving 93 prostate cancer patients.
• Three treatment arms: CAD, standard IAD, and modified IAD.
• Modified IAD involved a specific regimen of maximum androgen blockade (MAB) withdrawal and continuation of bicalutamide during intermittent periods.

Main Results:

• The modified IAD group showed a significantly longer median time to progression to AIPC (34.93 months) compared to CAD (26.50 months) and standard IAD (30.00 months).
• Kaplan-Meier analysis confirmed a significantly longer progression-free survival in the modified IAD group versus standard IAD.
• Modified IAD also resulted in longer treatment cycles and extended time off medication.

Conclusions:

• Modified intermittent androgen deprivation therapy is superior to continuous androgen deprivation and standard intermittent androgen deprivation in prolonging the time to progression to androgen-independent prostate cancer.
• This modified IAD strategy offers a promising approach for managing advanced prostate cancer.